Kawanishi, Japan

Kenzi Miyai


Average Co-Inventor Count = 4.0

ph-index = 11

Forward Citations = 236(Granted Patents)


Location History:

  • Hyogo, JP (1992)
  • Kawanishi, JP (1984 - 1997)

Company Filing History:


Years Active: 1984-1997

Loading Chart...
12 patents (USPTO):Explore Patents

Title: Kenzi Miyai: Innovator in Cephem Compounds

Introduction

Kenzi Miyai is a prominent inventor based in Kawanishi, Japan, known for his significant contributions to the field of pharmaceuticals. With a total of 12 patents to his name, he has made remarkable advancements in the development of cephem compounds.

Latest Patents

Miyai's latest patents include innovative cephem compounds and processes for their preparation. One of his notable inventions relates to new cephem compounds, which are pharmaceutically acceptable salts and pharmaceutical compositions that exhibit anti-bacterial properties. These cephem compounds feature a thiadiazine ring bonded to the cephem through an iminoacetamido chain, along with a pyrazolium ring connected via a methylene chain. Additionally, he has developed cephem compounds that demonstrate antimicrobial activity, characterized by a specific chemical formula.

Career Highlights

Kenzi Miyai has established a successful career at Fujisawa Pharmaceutical Company, Ltd., where he has been instrumental in advancing pharmaceutical research and development. His work has not only contributed to the company's reputation but has also had a lasting impact on the pharmaceutical industry.

Collaborations

Miyai has collaborated with notable colleagues, including Kazuo Sakane and Takao Takaya, to further enhance the research and development of innovative pharmaceutical solutions.

Conclusion

Kenzi Miyai's contributions to the field of cephem compounds highlight his dedication to pharmaceutical innovation. His work continues to influence the development of effective antimicrobial treatments, showcasing the importance of research in improving healthcare outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…